miR-367 promotes proliferation and stem-like traits in medulloblastoma cells

Cancer Science

Volumn 106, Issue 9, 2015, Pages 1188-1195

  Kaid, Carolini ^a   Silva, Patrícia B G ^a   Cortez, Beatriz A ^a   Rodini, Carolina O ^a   Semedo Kuriki, Patricia ^a   Okamoto, Oswaldo K ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cancer stem cell; Medulloblastoma; MicroRNA; MiR 367; Pluripotency

Indexed keywords

CD133 ANTIGEN; CD51 ANTIGEN; MICRORNA; MICRORNA 367; OCT4A PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; RYANODINE RECEPTOR 3; UNCLASSIFIED DRUG; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MIRN367 MICRORNA, HUMAN; PEPTIDE; POU5F1 PROTEIN, HUMAN; RAB PROTEIN; RAB23 PROTEIN, HUMAN; RYANODINE RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CELL FUNCTION; CELL INVASION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; CORRELATIONAL STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENETIC TRAIT; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDULLOBLASTOMA; MEDULLOBLASTOMA CELL LINE; MITOSIS INDEX; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SPHEROID CELL; STEM LIKE TRAIT; TUMOR SPHEROID; UPREGULATION; BRAIN TUMOR; GENETICS; MULTICELLULAR SPHEROID; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, CD; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GLYCOPROTEINS; HUMANS; MEDULLOBLASTOMA; MICRORNAS; OCTAMER TRANSCRIPTION FACTOR-3; PEPTIDES; RAB GTP-BINDING PROTEINS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SPHEROIDS, CELLULAR; UP-REGULATION;

EID: 84942191907     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12733     Document Type: Article

References (57)

1. Northcott PA, Dubuc AM, Pfister S, Taylor MD. Molecular subgroups of medulloblastoma. Expert Rev Neurother 2012; 12: 871-84.
2. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 2012; 14(Suppl 5): 1-49.
3. Gerber NU, Mynarek M, von Hoff K, Friedrich C, Resch A, Rutkowski S. Recent developments and current concepts in medulloblastoma. Cancer Treat Rev 2014; 40: 356-65.
4. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23-8.
5. Parsons DW, Li M, Zhang X et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011; 331: 435-9.
6. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011; 17: 320-9.
7. Taylor MD, Northcott PA, Korshunov A et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012; 123: 465-72.
8. Manoranjan B, Venugopal C, McFarlane N et al. Medulloblastoma stem cells: modeling tumor heterogeneity. Cancer Lett 2013; 338: 23-31.
9. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012; 21: 283-96.
10. Rodini CO, Suzuki DE, Nakahata AM et al. Aberrant signaling pathways in medulloblastomas: a stem cell connection. Arq Neuropsiquiatr 2010; 68: 947-52.
11. Marshall GM, Carter DR, Cheung BB et al. The prenatal origins of cancer. Nat Rev Cancer 2014; 14: 277-89.
12. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-7.
13. Lee AS, Tang C, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med 2013; 19: 998-1004.
14. Suzuki DE, Nakahata AM, Okamoto OK. Knockdown of E2F2 inhibits tumorigenicity, but preserves stemness of human embryonic stem cells. Stem Cells Dev 2014; 23: 1266-74.
15. Picard D, Miller S, Hawkins CE et al. Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol 2012; 13: 838-48.
16. Rodini CO, Suzuki DE, Saba-Silva N et al. Expression analysis of stem cell-related genes reveal OCT4 as a predictor of poor clinical outcome in medulloblastoma. J Neurooncol 2012; 106: 72-9.
17. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science 2013; 339: 1546-58.
18. Hovestadt V, Jones DTW, Picelli S et al. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature 2014; 510: 537-41.
19. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-72.
20. Anokye-Danso F, Trivedi CM, Juhr D et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 2011; 8: 376-88.
21. Houbaviy HB, Murray MF, Sharp PA. Embryonic stem cell-specific microRNAs. Dev Cell 2003; 5: 351-8.
22. Judson RL, Babiarz JE, Venere M, Blelloch R. Embryonic stem cell-specific microRNAs promote induced pluripotency. Nat Biotechnol 2009; 27: 459-61.
23. Zhang L, Liu Y, Song F et al. Functional SNP in the microRNA-367 binding site in the 3′UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification. Proc Natl Acad Sci U S A 2011; 108: 13653-8.
24. Kuo C-H, Deng JH, Deng Q, Ying S-Y. A novel role of miR-302/367 in reprogramming. Biochem Biophys Res Commun 2012; 417: 11-6.
25. Cai N, Wang Y-D, Zheng P-S. The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1. RNA 2013; 19: 85-95.
26. Wang Y, Baskerville S, Shenoy A, Babiarz JE, Baehner L, Blelloch R. Embryonic stem cell-specific microRNAs regulate the G1-S transition and promote rapid proliferation. Nat Genet 2008; 40: 1478-83.
27. Choi E, Choi E, Hwang K-C. MicroRNAs as novel regulators of atem cell fate. World J Stem Cells 2013; 5: 172-87.
28. Watson JA, Bryan K, Williams R et al. miRNA profiles as a predictor of chemoresponsiveness in Wilms' tumor blastema. PLoS One 2013; 8(1): e53417.
29. Costa FF, Bischof JM, Vanin EF et al. Identification of microRNAs as potential prognostic markers in ependymoma. PLoS One 2011; 6: e25114.
30. Campayo M, Navarro A, Viñolas N et al. Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer. Eur Respir J 2013; 41: 1172-8.
31. Syring I, Bartels J, Holdenrieder S, Kristiansen G, Müller SC, Ellinger J. Circulating serum microRNA (miR-367-3p, miR-371a-3p, miR-372-3p, miR-373-3p) as biomarkers for patients with testicular germ cell cancers. J Urol 2015; 193: 331-7.
32. Panosyan EH, Laks DR, Masterman-Smith M et al. Clinical outcome in pediatric glial and embryonal brain tumors correlates with in vitro multi-passageable neurosphere formation. Pediatr Blood Cancer 2010; 55: 644-51.
33. Venugopal C, Li N, Wang X et al. Bmi1 marks intermediate precursors during differentiation of human brain tumor initiating cells. Stem Cell Res 2012; 8: 141-53.
34. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-8.
35. Lavon I, Zrihan D, Granit A et al. Gliomas display a microRNA expression profile reminiscent of neural precursor cells. Neuro Oncol 2010; 12: 422-33.
36. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012; 10: 717-28.
37. Tirino V, Desiderio V, Paino F et al. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J 2013; 27: 13-24.
38. Zhao Z, Lu P, Zhang H et al. Nestin positively regulates the Wnt/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells. Breast Cancer Res 2014; 16: 408.
39. Bin Z, Dedong H, Xiangjie F, Hongwei X, Qinghui Y. The microRNA-367 inhibits the invasion and metastasis of gastric cancer by directly repressing Rab23. Genet Test Mol Biomarkers 2015; 19: 69-74.
40. Perris R, Perissinotto D. Role of the extracellular matrix during neural crest cell migration. Mech Dev 2000; 95: 3-21.
41. Reing JE, Zhang L, Myers-Irvin J et al. Degradation products of extracellular matrix affect cell migration and proliferation. Tissue Eng Part A 2009; 15: 605-14.
42. Hayashi H, Arao T, Togashi Y et al. The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer. Oncogene 2013; 34: 199-208.
43. Kim S-H, Singh SV. Mammary cancer chemoprevention by withaferin A is accompanied by in vivo suppression of self-renewal of cancer stem cells. Cancer Prev Res (Phila) 2014; 7: 738-47.
44. Teicher BA. Targets in small cell lung cancer. Biochem Pharmacol 2014; 87: 211-9.
45. Tsai L-L, Hu F-W, Lee S-S, Yu C-H, Yu C-C, Chang Y-C. Oct4 mediates tumor initiating properties in oral squamous cell carcinomas through the regulation of epithelial-mesenchymal transition. PLoS One 2014; 9: e87207.
46. Wang K, Wu X, Wang J, Huang J. Cancer stem cell theory: therapeutic implications for nanomedicine. Int J Nanomedicine 2013; 8: 899-908.
47. Lin S-L, Chang DC, Lin C-H, Ying S-Y, Leu D, Wu DTS. Regulation of somatic cell reprogramming through inducible mir-302 expression. Nucleic Acids Res 2011; 39: 1054-65.
48. Anokye-danso F, Trivedi CM, Juhr D et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell. 2011; 8: 376-88.
49. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 2000; 1: 11-21.
50. Northcott PA, Jones DTW, Kool M et al. Medulloblastomics: the end of the beginning. Nat Rev Cancer 2012; 12: 818-34.
51. Nordlund J, Milani L, Lundmark A, Lönnerholm G, Syvänen A-C. DNA methylation analysis of bone marrow cells at diagnosis of acute lymphoblastic leukemia and at remission. PLoS One 2012; 7: e34513.
52. Yang H, Rouse J, Lukes L et al. Caffeine suppresses metastasis in a transgenic mouse model: a prototype molecule for prophylaxis of metastasis. Clin Exp Metastasis 2004; 21: 719-35.
53. Lu Y-P, Lou Y-R, Xie J-G et al. Caffeine and caffeine sodium benzoate have a sunscreen effect, enhance UVB-induced apoptosis, and inhibit UVB-induced skin carcinogenesis in SKH-1 mice. Carcinogenesis 2007; 28: 199-206.
54. Jordens I, Marsman M, Kuijl C, Neefjes J. Rab proteins, connecting transport and vesicle fusion. Traffic 2005; 6: 1070-7.
55. Zhao J, Liu Y, Jian Q, Li J, Chi S. Role of Rab23 in invasion and migration of human breast cancer Bcap-37 cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2013; 29: 813-7.
56. Liu Q, Tang H, Liu X et al. miR-200b as a prognostic factor targets multiple members of RAB family in glioma. Med Oncol (Internet) 2014; 31: 859.
57. Eggenschwiler JT, Espinoza E, Anderson KV. Rab23 is an essential negative regulator of the mouse Sonic hedgehog signalling pathway. Nature 2001; 412: 194-8.